Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Total Current Liabilities for 16 consecutive years, with $145.2 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 45.19% to $145.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.2 million through Dec 2025, up 45.19% year-over-year, with the annual reading at $145.2 million for FY2025, 45.19% up from the prior year.
  • Total Current Liabilities hit $145.2 million in Q4 2025 for Vanda Pharmaceuticals, up from $117.9 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $145.2 million in Q4 2025 to a low of $61.8 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $93.1 million across 5 years, with a median of $91.1 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: soared 46.87% in 2022 and later decreased 8.41% in 2023.
  • Year by year, Total Current Liabilities stood at $74.4 million in 2021, then rose by 22.87% to $91.4 million in 2022, then dropped by 4.09% to $87.7 million in 2023, then grew by 14.01% to $100.0 million in 2024, then surged by 45.19% to $145.2 million in 2025.
  • Business Quant data shows Total Current Liabilities for VNDA at $145.2 million in Q4 2025, $117.9 million in Q3 2025, and $121.5 million in Q2 2025.